A Potential Error in Evaluating Cancer Screening: A Comparison of 2 Approaches for Modeling Underlying Disease Progression

Background. Evaluating cancer screening often requires modeling the underlying disease process and not observed disease, particularly in the absence of direct evidence linking screening to a survival benefit. Methods. To illustrate a potential error in modeling disease progression among healthy persons with a history of a precancerous lesion, we constructed 2 models with 4 basic health states (disease free, presence of a precancerous lesion, presence of cancer, dead), calibrated to predict the same 10-year cancer incidence. We assumed a homogeneous cohort enters each model free of disease, the probability of developing a precancerous lesion was greater for patients with a history of a prior lesion, and the screening test was perfect and riskless. In one model, we assigned a higher transition probability from a precancerous lesion to cancer in those with a history of a previously removed lesion; in the other, we assumed it was equal to those with no history. Results. Using the 1st model, life expectancy without screening was 2.4 months longer than with screening. This error did not occur using the 2nd model, in which the transition from precancerous lesions to cancer was not conditional on a history of a lesion. This modeling error's magnitude was examined under a variety of assumptions. Conclusions. We have identified an important error to avoid when modeling the underlying disease process in evaluating screening programs for cancers associated with precancerous states.

[1]  D. Eddy Screening for cervical cancer. , 1990, Annals of internal medicine.

[2]  M. Weinstein,et al.  The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. , 1999, JAMA.

[3]  L M Schuman,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[4]  M. Weinstein,et al.  The Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected Women , 1999, Annals of Internal Medicine.

[5]  M C Weinstein,et al.  Gains in life expectancy from medical interventions--standardizing data on outcomes. , 1998, The New England journal of medicine.

[6]  M. Weinstein,et al.  Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. , 2000, The American journal of medicine.

[7]  B R Luce,et al.  Health and economic outcomes modeling practices: a suggested framework. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  A. Miller An epidemiological perspective on cancer screening. , 1995, Clinical biochemistry.

[9]  K. Kuntz,et al.  Assessing the Sensitivity of Decision-Analytic Results to Unobserved Markers of Risk: Defining the Effects of Heterogeneity Bias , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  D C McCrory,et al.  Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.

[11]  V. Hasselblad,et al.  Evaluation of cervical cytology. , 1999, Evidence report/technology assessment.

[12]  David M. Eddy,et al.  Screening for cancer : theory, analysis, and design , 1984 .

[13]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  T. Church,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[15]  Graham A. Colditz,et al.  Cost-effectiveness of screening for colorectal cancer in the general population. , 2000, JAMA.